Invivyd (NASDAQ:IVVD) Receives Buy Rating from D. Boral Capital

D. Boral Capital restated their buy rating on shares of Invivyd (NASDAQ:IVVD) in a research report sent to investors on Thursday,Benzinga reports. They currently have a $9.00 price objective on the stock.

Several other analysts also recently issued reports on the company. HC Wainwright reduced their price target on Invivyd from $15.00 to $10.00 and set a “buy” rating for the company in a research note on Wednesday, November 20th. EF Hutton Acquisition Co. I raised Invivyd to a “strong-buy” rating in a report on Wednesday, October 30th. Finally, Morgan Stanley decreased their price target on shares of Invivyd from $9.50 to $3.55 and set an “overweight” rating on the stock in a research note on Wednesday, November 20th. Four research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $7.89.

Invivyd Stock Up 3.2 %

Invivyd stock opened at $0.72 on Thursday. Invivyd has a twelve month low of $0.69 and a twelve month high of $5.20. The stock has a market cap of $86.57 million, a P/E ratio of -0.36 and a beta of 0.65. The company’s 50-day moving average price is $0.97 and its two-hundred day moving average price is $1.22.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of IVVD. Duquesne Family Office LLC acquired a new stake in Invivyd during the second quarter worth about $629,000. Vanguard Group Inc. lifted its holdings in shares of Invivyd by 3.9% during the 1st quarter. Vanguard Group Inc. now owns 2,611,202 shares of the company’s stock worth $11,594,000 after acquiring an additional 97,496 shares during the period. Acadian Asset Management LLC boosted its position in shares of Invivyd by 232.0% during the 2nd quarter. Acadian Asset Management LLC now owns 678,706 shares of the company’s stock worth $745,000 after acquiring an additional 474,301 shares in the last quarter. Tidal Investments LLC bought a new position in Invivyd in the first quarter valued at approximately $126,000. Finally, Jacobs Levy Equity Management Inc. raised its position in Invivyd by 21.7% during the first quarter. Jacobs Levy Equity Management Inc. now owns 435,338 shares of the company’s stock valued at $1,933,000 after purchasing an additional 77,603 shares in the last quarter. Institutional investors own 70.36% of the company’s stock.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.